In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: Studies of the mode of action in Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2313-2323

  Robertson, Gregory T ^a   Bonventre, Eric J ^a,b   Doyle, Timothy B ^a,c   Du, Qun ^a   Duncan, Leonard ^a,c   Morris, Timothy W ^a,d   Roche, Eric D ^a,e   Yan, Dalai ^a,f   Lynch, A Simon ^a  

^a Cumbre Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

^d BAUSCH AND LOMB   (United States)

^e Healthpoint Ltd   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (3 AMINO 1 PYRROLIDINYL) 1 CYCLOPROPYL 7 FLUORO 9 METHYL 4 OXO 3 QUINOLIZINECARBOXYLIC ACID; BACTERIAL RNA; CBR 2092; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; LEVOFLOXACIN; QUINOLONE; RIFAMPICIN; RIFAMYCIN; RNA POLYMERASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; COVALENT BOND; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; IC 50; MACROMOLECULE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MUTATION; QUINOLONES; RIFAMYCINS; RNA, BACTERIAL; STAPHYLOCOCCUS AUREUS;

EID: 46249084681     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01649-07     Document Type: Article

References (44)

1. Acocella, G. 1983. Pharmacokinetics and metabolism of rifampin in humans. Rev. Infect. Dis. 5:S428-S432.
2. Alovero, F. L., X.-S. Pan, J. E. Morris, R. H. Manzo, and L. M. Fisher. 2000. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother. 44:320-325.
3. Amorena, B., E. Gracia, M. Monzon, J. Leiva, C. Oteiza, M. Perez, J. L. Alabart, and J. Hernandez-Yago. 1999. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J. Antimicrob. Chemother. 44:43-55.
4. Artsimovitch, I., M. N. Vassylyeva, D. Svetlov, V. Svetlov, A. Perederina, N. Igarashi, N. Matsugaki, S. Wakatsuki, T. H. Tahirov, and D. G. Vassylyev. 2005. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell 122:351-363.
5. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
6. Blaser, J., P. Vergeres, A. Widmer, and W. Zimmerli. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
7. Bryskier, A. 2005. Ansamycins. In Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington, DC.
8. Butler, M. M., W. A. LaMarr, K. A. Foster, M. H. Barnes, D. J. Skow, P. T. Lyden, L. M. Kustigian, C. Zhi, N. C. Brown, G. E. Wright, and T. L. Bowlin. 2007. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob. Agents Chemother. 51:119-127.
9. Campbell, E. A., N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, and S. A. Darst. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. Microbiol. 104:901-912.
10. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 7th ed. CLSI document M7-A7, vol. 26, no. 2. Clinical and Laboratory Standards Institute, Wayne, PA.
11. DeMarco, C. E., L. A. Cushing, E. Frempong-Manso, S. M. Seo, T. A. A. Jaravaza, and G. W. Kaatz. 2007. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 51:3235-3239.
12. Floss, H. G., and T.-W. Yu. 2005. Rifamycin-mode of action, resistance and biosynthesis. Chem. Rev. 105:621-632.
13. Gordeev, M. F., C. Hackbarth, M. R. Barbachyn, L. S. Banitt, J. R. Gage, G. W. Luehr, M. Gomez, J. Trias, S. E. Morin, G. E. Zurenko, C. N. Parker, J. M. Evans, R. J. White, and D. V. Patel. 2003. Novel oxazolidinone- quinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett. 13:4213-4216.
14. Gould, K. A., X.-S. Pan, R. J. Kerns, and L. M. Fisher. 2004. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48:2108-2115.
15. Hubschwerlen, C., J. L. Specklin, D. K. Baeschlin, Y. Borer, S. Haefeli, C. Sigwalt, S. Schroeder, and H. H. Locher. 2003. Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action. Bioorg. Med. Chem. Lett. 13:4229-4233.
16. Hubschwerlen, C., J. L. Specklin, C. Sigwalt, S. Schroeder, and H. H. Locher. 2003. Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids. Bioorg. Med. Chem. 11:2313-2319.
17. Ince, D., and D. C. Hooper. 2003. Quinolone resistance due to reduced target enzyme expression. J. Bacteriol. 185:6883-6892.
18. Ince, D., X. Zhang, L. C. Silver, and D. C. Hooper. 2002. Dual targeting of DNA gyrase and topoisomerase iv: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 46:3370-3380.
19. Kadurugamuwa, J. L., L. V. Sin, J. Yu, K. P. Francis, R. Kimura, T. Purchio, and P. R. Contag. 2003. Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. Antimicrob. Agents Chemother. 47:3130-3137.
20. Kadurugamuwa, J. L., L. V. Sin, J. Yu, K. P. Francis, T. F. Purchio, and P. R. Contag. 2004. Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo. Antimicrob. Agents Chemother. 48:2283-2287.
21. Karchmer, A. W. 2000. Infections of prosthetic heart valves, p. 145-172. In F. A. Waldvogel and A. L. Bisno (ed.), Infections associated with indwelling devices, 3rd ed. ASM Press, Washington, DC.
22. Kerns, R. J., M. J. Rybak, G. W. Kaatz, F. Vaka, R. Cha, R. G. Grucz, and V. U. Diwadkar. 2003. Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett. 13:2109-2112.
23. Kerns, R. J., M. J. Rybak, G. W. Kaatz, F. Vaka, R. Cha, R. G. Grucz, V. U. Diwadkar, and T. D. Ward. 2003. Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett. 13:1745-1749.
24. Konig, D. P., J. M. Schierholz, U. Munnich, and J. Rutt. 2001. Treatment of staphylococcal implant infection with rifampicin-ciprofloxacin in stable implants. Arch. Orthop Trauma Surg. 121:297-299.
25. Li, Q., D. T. Chu, A. Claiborne, C. S. Cooper, C. M. Lee, K. Raye, K. B. Berst, P. Donner, W. Wang, L. Hasvold, A. Fung, Z. Ma, M. Tufano, R. Flamm, L. L. Shen, J. Baranowski, A. Nilius, J. Alder, J. Meulbroek, K. Marsh, D. Crowell, Y. Hui, L. Seif, L. M. Melcher, R. Henry, S. Spanton, R. Faghih, L. L. Klein, S. K. Tanaka, and J. J. Plattner. 1996. Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. J. Med. Chem. 39:3070-3088.
26. Li, Q., L. A. Mitscher, and L. L. Shen. 2000. The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med. Res. Rev. 20:231-293.
27. Lynch, A. S., and Q. Du. 2007. Methods to identify and characterize inhibitors of bacterial RNA polymerase, p. 37-52. In New antibiotic targets. Molecular medicine series, Humana Press Inc., Totowa, NJ.
28. Lynch, A. S., E. J. Bonventre, T. B. Doyle, Q. Du, L. Duncan, G. T. Robertson, and E. D. Roche. 2007. In vitro mode-of-action studies of CBR-2092: a novel rifamycin-quinolone hybrid antibiotic, abstr. F1-2101. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
29. Monzon, M., C. Oteiza, J. Leiva, and B. Amorena. 2001. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. J. Antimicrob. Chemother. 48:793-801.
30. Pan, X.-S., P. J. Hamlyn, R. Talens-Visconti, F. L. Alovero, R. H. Manzo, and L. M. Fisher. 2002. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones. Antimicrob. Agents Chemother. 46:2498-2506.
31. Robertson, G. T., E. J. Bonventre, T. B. Doyle, Q. Du, L. Duncan, T. W. Morris, E. D. Roche, D. Yan, and A. S. Lynch. 2008. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob. Agents Chemother. 52:2324-2334.
32. Roychoudhury, S., T. L. Twinem, K. M. Makin, M. A. Nienaber, C. Li, T. W. Morris, B. Ledoussal, and C. E. Catrenich. 2001. Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations. Antimicrob. Agents Chemother. 45:3422-3426.
33. Saginur, R., M. Stdenis, W. Ferris, S. D. Aaron, F. Chan, C. Lee, and K. Ramotar. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50:55-61.
34. Saiki, A. Y., L. L. Shen, C. M. Chen, J. Baranowski, and C. G. Lerner. 1999. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob. Agents Chemother. 43:1574-1577.
35. Schmitz, F., A. Fluit, M. Luckefahr, B. Engler, B. Hofmann, J. Verhoef, H. Heinz, U. Hadding, and M. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42:807-810.
36. Schmitz, F. J., A. C. Fluit, S. Brisse, J. Verhoef, K. Kohrer, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287.
37. Schrenzel, J., S. Harbarth, G. Schockmel, D. Genne, T. Bregenzer, U. Flueckiger, C. Petignat, F. Jacobs, P. Francioli, W. Zimmerli, D. P. Lew, and Swiss Staphylococcal Study Group. 2004. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin. Infect. Dis. 39:1285-1292.
38. Schwank, S., Z. Rajacic, W. Zimmerli, and J. Blaser. 1998. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob. Agents Chemother. 42:895-898.
39. Stein, A., M. Drancourt, and D. Raoult. 2000. Management of infected orthopedic implants. In F. A. Waldvogel and A. L. Bisno (ed.), Infections associated with indwelling devices, 3rd ed. ASM Press, Washington, DC.
40. Tanaka, M., T. Wang, Y. Onodera, Y. Uchida, and K. Sato. 2000. Mechanism of quinolone resistance in Staphylococcus aureus. J. Infect. Chemother. 6:131-139.
41. Zhao, X., B. Quinn, R. Kerns, and K. Drlica. 2006. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 58:1283-1286.
42. Zheng, Z., and P. S. Stewart. 2002. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother. 46:900-903.
43. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
44. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, P. E. Ochsner, et al. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 279:1537-1541.